Beta-propeller protein-associated neurodegeneration (BPAN): A Patient Guide

Beta-propeller Protein-Associated Neurodegeneration (BPAN) is an ultra-rare genetic disorder that fundamentally changes how the brain’s cells recycle their own materials. Caused by a pathogenic variant in the WDR45 gene located on the X chromosome, this condition disrupts a vital process called autophagy—the cell’s “waste management” system. When this system fails, waste products and iron begin to accumulate in deep structures of the brain, leading to a unique clinical course that is unlike most other neurological conditions ^[1][2].

This condition is defined by its biphasic (two-phase) nature, meaning it presents in two distinct stages over a person’s life. In early childhood (Phase 1), the primary challenges are global developmental delays and a profound difficulty with expressive speech, though individuals often understand more than they can say. Epilepsy is also very common during these years, often requiring specialized management from a neurology team ^[3][4]. After a period of relative stability, the condition typically enters a second phase during adolescence or early adulthood (Phase 2), where new movement challenges such as parkinsonism (stiffness and tremors) and dystonia (involuntary muscle contractions) emerge alongside a gradual decline in cognitive skills ^[3][5].

Important Note on Variability: While this two-phase pattern is common, BPAN is highly variable. The phases can overlap, progression may begin earlier or later, and not everyone has the exact same milestones or seizure course. This guide describes broad patterns, not a strict timetable for any one person.

Because BPAN evolves over time, the diagnostic journey can be complex. In young children, brain scans using MRI (Magnetic Resonance Imaging) may appear entirely normal or show only subtle, non-specific changes. It is often not until the second phase of the disease that a highly suggestive sign of BPAN—the T1 substantia nigra halo, representing iron accumulation and other complex tissue changes—becomes visible on imaging. For this reason, many families experience a long search for answers, which is ultimately resolved through definitive genetic testing to identify the WDR45 pathogenic variant ^[6][7].

While there is currently no cure to stop or reverse the progression of BPAN, families find strength in a proactive, multidisciplinary approach to care. Management is supportive, focusing on physical, occupational, and speech therapies that adapt to each person’s needs as they grow. By coordinating a team of specialists—including neurologists, geneticists, and therapists—families can focus on maximizing comfort, communication, and quality of life at every stage of the journey ^[3][8]. Despite the challenges of this rare diagnosis, you are now part of a dedicated community of researchers and families working together to improve care and search for future treatments.